Targeting Iron Responsive Elements (IREs) of APP mRNA into Novel Therapeutics to Control the Translation of Amyloid-β Precursor Protein in Alzheimer’s Disease. Here, APP is linked to early-onset autosomal dominant Alzheimer disease.